# Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants

> **NCT04351685** · PHASE3 · COMPLETED · sponsor: **Serum Institute of India Pvt. Ltd.** · enrollment: 6940 (actual)

## Conditions studied

- Mycobacterium Tuberculosis Infection

## Interventions

- **BIOLOGICAL:** VPM1002
- **BIOLOGICAL:** BCG SII

## Key facts

- **NCT ID:** NCT04351685
- **Lead sponsor:** Serum Institute of India Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-09
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 6940 (ACTUAL)
- **Last updated:** 2025-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04351685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04351685, "Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04351685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*